RxDoctor Payments Data

Roberto Nieto, MD

Neurology · Mansfield, TXNPI 1750430419

Payments from drug & device makers

$324,015in general payments, 2019–2025

Across 1,541 payments — averaging $210.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$86K
  • Eisai Inc.$68K
  • Amgen$39K
  • AbbVie$37K
  • Teva Pharmaceuticals USA, Inc.$17K
  • Supernus Pharmaceuticals, Inc.$16K
  • plus $61K from 54 others

What the payments were for

  • Consulting fees$11,9665%
  • Speaking & faculty fees$193,42179%
  • Travel & lodging$11,0364%
  • Food & beverage$28,88712%
  • Education$6330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.158$85,727
Eisai Inc.80$67,958
Amgen(2 entities)80$39,253
AbbVie(2 entities)284$36,854
Teva Pharmaceuticals USA, Inc.78$17,466
Supernus Pharmaceuticals, Inc.65$15,658
Axsome Therapeutics, Inc.12$12,709
Impel Pharmaceuticals Inc.7$9,267
SK Life Science, Inc.28$7,334
Novartis26$3,495
Biohaven Pharmaceuticals, Inc.22$3,412
UCB, Inc.72$3,273
UCB SA2$3,120
Avanir Pharmaceuticals, Inc.15$2,726
Pfizer41$1,793
Biogen77$1,603
Upsher-smith Laboratories LLC25$1,577
Kyowa Kirin, Inc.17$1,506
Jazz Pharmaceuticals Inc.30$893
Neurocrine Biosciences, Inc.33$766
Lundbeck LLC31$517
Lilly USA, LLC30$461
Sanofi20$450
Amneal Pharmaceuticals LLC19$356
Genentech USA, Inc.10$332
Sunovion Pharmaceuticals Inc.28$295
Idorsia Pharmaceuticals US Inc9$278
Currax Pharmaceuticals LLC23$263
Arbor Pharmaceuticals, Inc.17$262
TG Therapeutics, Inc.10$261
Biohaven Pharmaceutical Holding Company Ltd.15$243
Harmony Biosciences LLC12$242
MDD US Operations, LLC5$223
Merck14$223
Otsuka America Pharmaceutical, Inc.7$190
Vanda Pharmaceuticals Inc.9$182
Acadia Pharmaceuticals Inc8$170
AstraZeneca(2 entities)8$167
Almatica Pharma LLC9$161
Acorda Therapeutics, Inc8$151
Avadel CNS Pharmaceuticals, LLC7$146
Inspire Medical Systems, Inc.1$145
Takeda Pharmaceuticals U.S.A., Inc.6$129
Argenx US, Inc.6$125
Bristol Myers Squibb6$123
Impel Pharmaceuticals LLC8$120
Ipsen Biopharmaceuticals, Inc1$108
Johnson & Johnson(2 entities)5$92
3b Medical, Inc.1$92
Banner Life Sciences, LLC4$86
Neurelis, Inc.5$81
Corium, LLC3$79
Tanabe Pharma America, Inc.4$78
Adamas Pharmaceuticals, Inc.4$70
Validus Pharmaceuticals LLC3$70
Abbott3$66
Boston Scientific2$62
Aucta Pharmaceuticals, Inc.2$55
Grifols USA, LLC3$54
Catalyst Pharmaceuticals, Inc.3$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$324,015 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$150,987
Medicare patients
355
Services billed
9,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate25$220,144
Austedo XrDeutetrabenazine33$201,202
NuplazidPimavanserin Tartrate29$194,053
AustedoDeutetrabenazine20$183,817
Nurtec OdtRimegepant Sulfate88$149,644
BelsomraSuvorexant145$81,261
NourianzIstradefylline31$76,362
UbrelvyUbrogepant51$70,142
CopaxoneGlatiramer Acetate12$69,984
Aimovig AutoinjectorErenumab-Aooe56$57,837
RytaryCarbidopa/Levodopa23$52,570
Emgality PenGalcanezumab-Gnlm37$42,512
VimpatLacosamide20$39,539
QuliptaAtogepant34$39,364
Ajovy AutoinjectorFremanezumab-Vfrm40$33,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Copaxone$17,466$455,00265 claims
BiogenVumerity$1,603$220,14425 claims
Acadia Pharmaceuticals IncNuplazid$170$194,05329 claims
PfizerNurtec Odt$1,793$149,64488 claims
AbbVieUbrelvy, Qulipta$36,854$109,50685 claims
MerckBelsomra$223$81,261145 claims
Kyowa Kirin, Inc.Nourianz$1,506$76,36231 claims
UCB, Inc.Vimpat, Briviact$3,273$59,53132 claims
Amneal Pharmaceuticals LLCRytary$356$52,57023 claims
SK Life Science, Inc.Xcopri$7,334$29,74924 claims
Eisai Inc.Fycompa$67,958$27,36923 claims
Otsuka America Pharmaceutical, Inc.Rexulti$190$22,28714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →